Arrayit Corporation

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, LZAGY has a market cap of 46B. Regarding current trading prices, ARYC is priced at $0.00, while LZAGY trades at $64.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas LZAGY's P/E ratio is 39.70. In terms of profitability, ARYC's ROE is +0.55%, compared to LZAGY's ROE of +0.11%. Regarding short-term risk, ARYC is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check LZAGY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, WUXAY has a market cap of 45B. Regarding current trading prices, ARYC is priced at $0.00, while WUXAY trades at $15.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas WUXAY's P/E ratio is 16.39. In terms of profitability, ARYC's ROE is +0.55%, compared to WUXAY's ROE of +0.28%. Regarding short-term risk, ARYC is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check WUXAY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, LZAGF has a market cap of 43.8B. Regarding current trading prices, ARYC is priced at $0.00, while LZAGF trades at $643.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas LZAGF's P/E ratio is 38.42. In terms of profitability, ARYC's ROE is +0.55%, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, ARYC is more volatile compared to LZAGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check LZAGF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, ARYC is priced at $0.00, while WUXIF trades at $13.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas WUXIF's P/E ratio is 14.46. In terms of profitability, ARYC's ROE is +0.55%, compared to WUXIF's ROE of +0.28%. Regarding short-term risk, ARYC is more volatile compared to WUXIF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check WUXIF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ERFSF has a market cap of 13.5B. Regarding current trading prices, ARYC is priced at $0.00, while ERFSF trades at $76.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ERFSF's P/E ratio is 25.98. In terms of profitability, ARYC's ROE is +0.55%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, ARYC is more volatile compared to ERFSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ERFSF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, BMXMF has a market cap of 12.1B. Regarding current trading prices, ARYC is priced at $0.00, while BMXMF trades at $102.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas BMXMF's P/E ratio is 26.56. In terms of profitability, ARYC's ROE is +0.55%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, ARYC is more volatile compared to BMXMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check BMXMF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SKHHY has a market cap of 7B. Regarding current trading prices, ARYC is priced at $0.00, while SKHHY trades at $14.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SKHHY's P/E ratio is 18.55. In terms of profitability, ARYC's ROE is +0.55%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, ARYC is more volatile compared to SKHHY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SKHHY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SKHCF has a market cap of 6.6B. Regarding current trading prices, ARYC is priced at $0.00, while SKHCF trades at $13.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SKHCF's P/E ratio is 17.97. In terms of profitability, ARYC's ROE is +0.55%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, ARYC is more volatile compared to SKHCF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SKHCF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, ARYC is priced at $0.00, while HNGZY trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, ARYC's ROE is +0.55%, compared to HNGZY's ROE of +0.03%. Regarding short-term risk, ARYC is more volatile compared to HNGZY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check HNGZY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, DSRLF has a market cap of 3.6B. Regarding current trading prices, ARYC is priced at $0.00, while DSRLF trades at $67.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas DSRLF's P/E ratio is 20.49. In terms of profitability, ARYC's ROE is +0.55%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, ARYC is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check DSRLF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, ARYC is priced at $0.00, while VIMGF trades at $2.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, ARYC's ROE is +0.55%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, ARYC is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check VIMGF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, ARYC is priced at $0.00, while GNTLF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, ARYC's ROE is +0.55%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, ARYC is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check GNTLF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, MRCHF has a market cap of 1.3B. Regarding current trading prices, ARYC is priced at $0.00, while MRCHF trades at $22.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas MRCHF's P/E ratio is 70.97. In terms of profitability, ARYC's ROE is +0.55%, compared to MRCHF's ROE of +0.04%. Regarding short-term risk, ARYC is more volatile compared to MRCHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check MRCHF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IDGXF has a market cap of 372M. Regarding current trading prices, ARYC is priced at $0.00, while IDGXF trades at $0.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IDGXF's P/E ratio is 21.33. In terms of profitability, ARYC's ROE is +0.55%, compared to IDGXF's ROE of +0.38%. Regarding short-term risk, ARYC is more volatile compared to IDGXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IDGXF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, EDTXF has a market cap of 289.1M. Regarding current trading prices, ARYC is priced at $0.00, while EDTXF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas EDTXF's P/E ratio is -8.33. In terms of profitability, ARYC's ROE is +0.55%, compared to EDTXF's ROE of +0.88%. Regarding short-term risk, ARYC is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check EDTXF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, ARYC is priced at $0.00, while AMCY trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas AMCY's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to AMCY's ROE of N/A. Regarding short-term risk, ARYC is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check AMCY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, ARYC is priced at $0.00, while NNGRF trades at $12.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, ARYC's ROE is +0.55%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, ARYC is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check NNGRF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, ARYC is priced at $0.00, while DIUXF trades at $1.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, ARYC's ROE is +0.55%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, ARYC is more volatile compared to DIUXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check DIUXF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, CORBF has a market cap of 140.6M. Regarding current trading prices, ARYC is priced at $0.00, while CORBF trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas CORBF's P/E ratio is 3.00. In terms of profitability, ARYC's ROE is +0.55%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, ARYC is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check CORBF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, LDXHF has a market cap of 128.8M. Regarding current trading prices, ARYC is priced at $0.00, while LDXHF trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas LDXHF's P/E ratio is -16.15. In terms of profitability, ARYC's ROE is +0.55%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, ARYC is more volatile compared to LDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check LDXHF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, ARYC is priced at $0.00, while THOXF trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas THOXF's P/E ratio is -7.45. In terms of profitability, ARYC's ROE is +0.55%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, ARYC is more volatile compared to THOXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check THOXF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, ARYC is priced at $0.00, while TIHE trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas TIHE's P/E ratio is 0.32. In terms of profitability, ARYC's ROE is +0.55%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, ARYC is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check TIHE's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, PFGTF has a market cap of 69.8M. Regarding current trading prices, ARYC is priced at $0.00, while PFGTF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas PFGTF's P/E ratio is -3.41. In terms of profitability, ARYC's ROE is +0.55%, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, ARYC is more volatile compared to PFGTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check PFGTF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, ARYC is priced at $0.00, while BIOGF trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, ARYC's ROE is +0.55%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, ARYC is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check BIOGF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, ARYC is priced at $0.00, while PCNEF trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, ARYC's ROE is +0.55%, compared to PCNEF's ROE of -0.06%. Regarding short-term risk, ARYC is more volatile compared to PCNEF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check PCNEF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, BMKDF has a market cap of 45.9M. Regarding current trading prices, ARYC is priced at $0.00, while BMKDF trades at $0.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas BMKDF's P/E ratio is -43.68. In terms of profitability, ARYC's ROE is +0.55%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, ARYC is more volatile compared to BMKDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check BMKDF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, BIOQ has a market cap of 33.5M. Regarding current trading prices, ARYC is priced at $0.00, while BIOQ trades at $37.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas BIOQ's P/E ratio is 15.83. In terms of profitability, ARYC's ROE is +0.55%, compared to BIOQ's ROE of +0.01%. Regarding short-term risk, ARYC is more volatile compared to BIOQ. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check BIOQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SNANF has a market cap of 27M. Regarding current trading prices, ARYC is priced at $0.00, while SNANF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SNANF's P/E ratio is -11.80. In terms of profitability, ARYC's ROE is +0.55%, compared to SNANF's ROE of -4.34%. Regarding short-term risk, ARYC is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SNANF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, ARYC is priced at $0.00, while ANPCY trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, ARYC's ROE is +0.55%, compared to ANPCY's ROE of -1.05%. Regarding short-term risk, ARYC is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ANPCY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, ARYC is priced at $0.00, while PCHM trades at $3.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas PCHM's P/E ratio is -0.02. In terms of profitability, ARYC's ROE is +0.55%, compared to PCHM's ROE of +0.36%. Regarding short-term risk, ARYC is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check PCHM's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, ARYC is priced at $0.00, while VILGF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas VILGF's P/E ratio is -0.30. In terms of profitability, ARYC's ROE is +0.55%, compared to VILGF's ROE of N/A. Regarding short-term risk, ARYC is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check VILGF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, ARYC is priced at $0.00, while CLIFF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, ARYC's ROE is +0.55%, compared to CLIFF's ROE of -0.12%. Regarding short-term risk, ARYC is more volatile compared to CLIFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check CLIFF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, ARYC is priced at $0.00, while LDDD trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas LDDD's P/E ratio is -51.00. In terms of profitability, ARYC's ROE is +0.55%, compared to LDDD's ROE of -0.28%. Regarding short-term risk, ARYC is more volatile compared to LDDD. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check LDDD's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ABDXF has a market cap of 13.3M. Regarding current trading prices, ARYC is priced at $0.00, while ABDXF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, ARYC's ROE is +0.55%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, ARYC is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ABDXF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IZOZF has a market cap of 10.9M. Regarding current trading prices, ARYC is priced at $0.00, while IZOZF trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IZOZF's P/E ratio is -8.04. In terms of profitability, ARYC's ROE is +0.55%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, ARYC is more volatile compared to IZOZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IZOZF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, ARYC is priced at $0.00, while MXDHF trades at $0.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, ARYC's ROE is +0.55%, compared to MXDHF's ROE of +5.17%. Regarding short-term risk, ARYC is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check MXDHF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IDXG has a market cap of 8.1M. Regarding current trading prices, ARYC is priced at $0.00, while IDXG trades at $1.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IDXG's P/E ratio is -2.79. In terms of profitability, ARYC's ROE is +0.55%, compared to IDXG's ROE of +4.85%. Regarding short-term risk, ARYC is more volatile compared to IDXG. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IDXG's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, ARYC is priced at $0.00, while JMPHF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, ARYC's ROE is +0.55%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, ARYC is more volatile compared to JMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check JMPHF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, ARYC is priced at $0.00, while IMMVF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, ARYC's ROE is +0.55%, compared to IMMVF's ROE of -5.64%. Regarding short-term risk, ARYC is more volatile compared to IMMVF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IMMVF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, ARYC is priced at $0.00, while SQIDF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, ARYC's ROE is +0.55%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, ARYC is more volatile compared to SQIDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SQIDF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, PMSNF has a market cap of 5.3M. Regarding current trading prices, ARYC is priced at $0.00, while PMSNF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, ARYC's ROE is +0.55%, compared to PMSNF's ROE of +0.44%. Regarding short-term risk, ARYC is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check PMSNF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, AVCRF has a market cap of 4.6M. Regarding current trading prices, ARYC is priced at $0.00, while AVCRF trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas AVCRF's P/E ratio is -4.51. In terms of profitability, ARYC's ROE is +0.55%, compared to AVCRF's ROE of -0.95%. Regarding short-term risk, ARYC is more volatile compared to AVCRF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check AVCRF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, ARYC is priced at $0.00, while VRCDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, ARYC's ROE is +0.55%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, ARYC is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for ARYC.Check VRCDF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, ARYC is priced at $0.00, while RNVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas RNVA's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, ARYC is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check RNVA's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ANPCF has a market cap of 4.2M. Regarding current trading prices, ARYC is priced at $0.00, while ANPCF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ANPCF's P/E ratio is -0.21. In terms of profitability, ARYC's ROE is +0.55%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, ARYC is more volatile compared to ANPCF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ANPCF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ICBU has a market cap of 3.9M. Regarding current trading prices, ARYC is priced at $0.00, while ICBU trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ICBU's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to ICBU's ROE of +0.20%. Regarding short-term risk, ARYC is more volatile compared to ICBU. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ICBU's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, TDSGF has a market cap of 3.6M. Regarding current trading prices, ARYC is priced at $0.00, while TDSGF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas TDSGF's P/E ratio is -3.60. In terms of profitability, ARYC's ROE is +0.55%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, ARYC is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check TDSGF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IBXXF has a market cap of 2.5M. Regarding current trading prices, ARYC is priced at $0.00, while IBXXF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IBXXF's P/E ratio is -1.12. In terms of profitability, ARYC's ROE is +0.55%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, ARYC is more volatile compared to IBXXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IBXXF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IVRO has a market cap of 1.9M. Regarding current trading prices, ARYC is priced at $0.00, while IVRO trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IVRO's P/E ratio is -0.78. In terms of profitability, ARYC's ROE is +0.55%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, ARYC is more volatile compared to IVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IVRO's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, ARYC is priced at $0.00, while CHHL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas CHHL's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, ARYC is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for ARYC.Check CHHL's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SLDX has a market cap of 1.6M. Regarding current trading prices, ARYC is priced at $0.00, while SLDX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SLDX's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to SLDX's ROE of +0.06%. Regarding short-term risk, ARYC is more volatile compared to SLDX. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SLDX's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, ARYC is priced at $0.00, while DIGP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas DIGP's P/E ratio is -1.04. In terms of profitability, ARYC's ROE is +0.55%, compared to DIGP's ROE of +1.19%. Regarding short-term risk, ARYC is more volatile compared to DIGP. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check DIGP's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, ARYC is priced at $0.00, while EPGNF trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, ARYC's ROE is +0.55%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, ARYC is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check EPGNF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, ARYC is priced at $0.00, while RSHN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas RSHN's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, ARYC is more volatile compared to RSHN. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check RSHN's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IDTA has a market cap of 708K. Regarding current trading prices, ARYC is priced at $0.00, while IDTA trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IDTA's P/E ratio is 1.75. In terms of profitability, ARYC's ROE is +0.55%, compared to IDTA's ROE of -0.09%. Regarding short-term risk, ARYC is more volatile compared to IDTA. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check IDTA's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, ARYC is priced at $0.00, while SZLSF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, ARYC's ROE is +0.55%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, ARYC is more volatile compared to SZLSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SZLSF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, ARYC is priced at $0.00, while SCRSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, ARYC's ROE is +0.55%, compared to SCRSF's ROE of +1.14%. Regarding short-term risk, ARYC is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check SCRSF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, ARYC is priced at $0.00, while NSTM trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas NSTM's P/E ratio is 0.20. In terms of profitability, ARYC's ROE is +0.55%, compared to NSTM's ROE of -0.83%. Regarding short-term risk, ARYC is more volatile compared to NSTM. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check NSTM's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, ARYC is priced at $0.00, while MBGNF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, ARYC's ROE is +0.55%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, ARYC is more volatile compared to MBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check MBGNF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, ARYC is priced at $0.00, while NVTAQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, ARYC's ROE is +0.55%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, ARYC is more volatile compared to NVTAQ. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check NVTAQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, ARYC is priced at $0.00, while HCLC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas HCLC's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, ARYC is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check HCLC's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, MEDD has a market cap of 63.8K. Regarding current trading prices, ARYC is priced at $0.00, while MEDD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas MEDD's P/E ratio is -0.02. In terms of profitability, ARYC's ROE is +0.55%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, ARYC is more volatile compared to MEDD. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check MEDD's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, IHTI has a market cap of 32.5K. Regarding current trading prices, ARYC is priced at $0.00, while IHTI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas IHTI's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, ARYC is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for ARYC.Check IHTI's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, ARYC is priced at $0.00, while TOMDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas TOMDF's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, ARYC is more volatile compared to TOMDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check TOMDF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, ARYC is priced at $0.00, while CGNH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas CGNH's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, ARYC is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check CGNH's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, ARYC is priced at $0.00, while ABMC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ABMC's P/E ratio is 0.01. In terms of profitability, ARYC's ROE is +0.55%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, ARYC is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ABMC's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, ARYC is priced at $0.00, while CYPS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas CYPS's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to CYPS's ROE of N/A. Regarding short-term risk, ARYC is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check CYPS's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, ARYC is priced at $0.00, while RGDXQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, ARYC and RGDXQ have similar daily volatility (196.04).Check RGDXQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, ARYC is priced at $0.00, while DMTKQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, ARYC's ROE is +0.55%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, ARYC is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check DMTKQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, ARYC is priced at $0.00, while MEDVF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas MEDVF's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, ARYC is more volatile compared to MEDVF. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check MEDVF's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, ARYC is priced at $0.00, while GWHP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas GWHP's P/E ratio is -0.00. In terms of profitability, ARYC's ROE is +0.55%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, ARYC is more volatile compared to GWHP. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check GWHP's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, ARYC is priced at $0.00, while ROSGQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, ARYC is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check ROSGQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, ARYC is priced at $0.00, while BIOCQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, ARYC is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check BIOCQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, ARYC is priced at $0.00, while HTGMQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, ARYC is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check HTGMQ's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, OPGX has a market cap of 17. Regarding current trading prices, ARYC is priced at $0.00, while OPGX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas OPGX's P/E ratio is -0.00. In terms of profitability, ARYC's ROE is +0.55%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, ARYC is more volatile compared to OPGX. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check OPGX's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, ARYC is priced at $0.00, while EPGNY trades at $2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, ARYC's ROE is +0.55%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, ARYC is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check EPGNY's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, MRPS has a market cap of 0. Regarding current trading prices, ARYC is priced at $0.00, while MRPS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas MRPS's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to MRPS's ROE of N/A. Regarding short-term risk, ARYC is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check MRPS's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, BGNX has a market cap of 0. Regarding current trading prices, ARYC is priced at $0.00, while BGNX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas BGNX's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to BGNX's ROE of N/A. Regarding short-term risk, ARYC is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check BGNX's competition here

ARYC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARYC stands at 79.3K. In comparison, AGHC has a market cap of 0. Regarding current trading prices, ARYC is priced at $0.00, while AGHC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARYC currently has a P/E ratio of N/A, whereas AGHC's P/E ratio is N/A. In terms of profitability, ARYC's ROE is +0.55%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, ARYC is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for ARYC.Check AGHC's competition here